Wednesday, July 8, 2026

biotech · Coronary Artery Disease · Bronchopulmonary Dysplasia · ASBP

Aspire Biopharma Holdings

Aspire Biopharma is a biotech organization headquartered in Humacao, USA. It trades on NYSE under ticker ASBP. Primary therapeutic focus areas include Coronary Artery Disease, Bronchopulmonary Dysplasia, Heart Failure, C

Humacao, USA HQ
2019 Founded
Public company Type
ASBP · NYSE Ticker
Company details
Status
Public
HQ
Humacao, USA
Founded
2019
Programs
8
Drugs
8
Patents
1
Clinical program

Myocardial perfusion imaging

Approved · other · Coronary Artery Disease

Myocardial perfusion imaging for Coronary Artery Disease is a Approved program (other) at Aspire Biopharma Holdings with 1 ClinicalTrials.gov record(s).

Internal code 09-307

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Aspire Biopharma Holdings
Phase
Approved
Modality
other
Indication
Coronary Artery Disease
Status
completed
Trials
1